The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms in patients with chronic heArt faiLure) trials evaluated the effect of 10 mg empagliflozin versus placebo on exercise ability in patients with heart failure. EMPERIAL-Reduced (NCT03448419) randomized 312 patients with heart failure with reduced ejection fraction (LVEF ≤ 40%) to receive either … [Read more...] about Effect of Empagliflozin on exercise ability and symptoms in heart failure patients
Interventional cardiology
Renin-angiotensin system inhibitors improve transcatheter aortic valve replacement prognosis
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to replace narrowed aortic valves that fail to properly open. Following this procedure, however, left ventricular (LV) hypertrophy and myocardial fibrosis persist and are linked to worse prognosis. Renin-angiotensin system (RAS) inhibition can protect against these risks and in response to … [Read more...] about Renin-angiotensin system inhibitors improve transcatheter aortic valve replacement prognosis
ARTICA Trial: Research in Progress
The ARTICA (“Acute Rule out of non ST-segment elevation acute coronary syndrome in the (pre)hospital setting”) trial is being conducted at Radboud UMC in Nijmegen, the Netherlands. Dr. Cyril Camaro and his team started this randomized, 2-arm trial in March 2019 and plan to finish March 2022. The objective of the ARTICA trial is to assess cost-effectiveness and efficacy of … [Read more...] about ARTICA Trial: Research in Progress
Top Cardiology Conferences 2021
With the COVID-19 worldwide pandemic, conferences and congresses planned for 2020 converted to either a digital format or were cancelled. Looking ahead to 2021, conferences planned for the first quarter will still proceed virtually. Many of the most popular and well attended conferences occurring later in the year hope to proceed once again in-person. However, they are keeping … [Read more...] about Top Cardiology Conferences 2021
SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include elevated hepatic or muscular enzymes, neurological symptoms, and muscular symptoms collectively referred to as statin-associated muscle symptoms (SAMS).1 SAMS seems to occur less frequently in randomized control trials than in observational studies. These results suggest that … [Read more...] about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms